moclobemide has been researched along with Depressive Disorder, Major in 13 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "For new MAO-A inhibitors, about 74% occupancy at steady-state dosing is desirable." | 2.76 | Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. ( Houle, S; Meyer, JH; Parkes, J; Rusjan, P; Sacher, J; Sagrati, S; Wilson, AA, 2011) |
| "From a clinical point of view, orthostatic hypotension is a significant side effect during antidepressant treatment, particularly in the case of tricyclic antidepressants (TCAs)." | 2.71 | Orthostatic side effects of clomipramine and moclobemide during treatment for depression. ( Stage, KB, 2005) |
| "Sertraline was well tolerated." | 2.69 | An open study of sertraline in patients with major depression who failed to respond to moclobemide. ( Chiu, E; George, T; Hokin, A; Krapivensky, N; Theodoros, MT; Tiller, JW, 1999) |
| " A metaregression did not reveal a statistically significant relation between the mean moclobemide dosage for each study and the risk ratio for response rates." | 2.43 | A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. ( Fava, M; Papakostas, GI, 2006) |
| "Treatment-resistant depression is a major depressive disorder that does not respond to adequate treatment of at least two antidepressants and is one of the major clinical challenges for clinicians and clinical pharmacists." | 1.43 | Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case. ( Oravecz, R; Stuhec, M, 2016) |
| " We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d." | 1.42 | Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015) |
| "Moclobemide has negative immunoregulatory capacities through inhibition of the production of proinflammatory cytokines, i." | 1.31 | The in vitro immunosuppressive effects of moclobemide in healthy volunteers. ( Bosmans, E; De Jongh, R; Kenis, G; Lin, A; Maes, M; Scharpé, S; Song, C, 2000) |
| "Musical hallucinations are the hearing of tunes, melodies, harmonics, rhythms and timbres." | 1.31 | Musical hallucinations associated with abruptly developed bilateral loss of hearing. ( Ozçürümez, G; Sayilgan, MA; Tanriverdi, N, 2001) |
| " This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic." | 1.31 | Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. ( Bagby, RM; Kennedy, SH; Vanderkooy, JD, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayasaka, Y | 1 |
| Purgato, M | 1 |
| Magni, LR | 1 |
| Ogawa, Y | 1 |
| Takeshima, N | 1 |
| Cipriani, A | 1 |
| Barbui, C | 1 |
| Leucht, S | 1 |
| Furukawa, TA | 1 |
| Stuhec, M | 1 |
| Oravecz, R | 1 |
| Sacher, J | 1 |
| Houle, S | 1 |
| Parkes, J | 1 |
| Rusjan, P | 1 |
| Sagrati, S | 1 |
| Wilson, AA | 1 |
| Meyer, JH | 1 |
| Bech, P | 1 |
| Stage, KB | 2 |
| Larsen, JK | 1 |
| Vestergaard, P | 1 |
| Gram, LF | 1 |
| Henkel, V | 1 |
| Mergl, R | 1 |
| Allgaier, AK | 1 |
| Kohnen, R | 1 |
| Möller, HJ | 1 |
| Hegerl, U | 1 |
| Papakostas, GI | 1 |
| Fava, M | 1 |
| Jimenez-Genchi, A | 1 |
| George, T | 1 |
| Theodoros, MT | 1 |
| Chiu, E | 1 |
| Krapivensky, N | 1 |
| Hokin, A | 1 |
| Tiller, JW | 1 |
| Lin, A | 1 |
| Song, C | 1 |
| Kenis, G | 1 |
| Bosmans, E | 1 |
| De Jongh, R | 1 |
| Scharpé, S | 1 |
| Maes, M | 1 |
| Bekaroğlu, M | 1 |
| Değer, O | 1 |
| Karahan, SC | 1 |
| Bilici, M | 1 |
| Soylu, C | 1 |
| Orem, A | 1 |
| Tanriverdi, N | 1 |
| Sayilgan, MA | 1 |
| Ozçürümez, G | 1 |
| Vanderkooy, JD | 1 |
| Kennedy, SH | 1 |
| Bagby, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome[NCT05174273] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2022-04-06 | Recruiting | ||
| A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder[NCT03279224] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for moclobemide and Depressive Disorder, Major
| Article | Year |
|---|---|
Treatment of depression with atypical features: a meta-analytic approach.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Moclobemide; Monoami | 2006 |
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Depressive Disorder, Major; Disorders of Excessive Somnolence; Fatigue; Headache; Humans; Imipramine | 2006 |
4 trials available for moclobemide and Depressive Disorder, Major
| Article | Year |
|---|---|
Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.
Topics: Adult; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Female; Harmine; Humans; Hypericum; | 2011 |
The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder, Major; Double-Blind Method; Fem | 2012 |
Orthostatic side effects of clomipramine and moclobemide during treatment for depression.
Topics: Adult; Aged; Antidepressive Agents; Clomipramine; Depressive Disorder, Major; Drug Administration Sc | 2005 |
An open study of sertraline in patients with major depression who failed to respond to moclobemide.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Rel | 1999 |
7 other studies available for moclobemide and Depressive Disorder, Major
| Article | Year |
|---|---|
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose | 2015 |
Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case.
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Dru | 2016 |
Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Duloxetine Hydrochloride; Fema | 2006 |
The in vitro immunosuppressive effects of moclobemide in healthy volunteers.
Topics: Adult; Antidepressive Agents; Cytokines; Depressive Disorder, Major; Female; Humans; Immune Toleranc | 2000 |
Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Maj | 2000 |
Musical hallucinations associated with abruptly developed bilateral loss of hearing.
Topics: Adult; Atrophy; Brain; Depressive Disorder, Major; Electroencephalography; Female; Hallucinations; H | 2001 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan | 2002 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan | 2002 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan | 2002 |
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexan | 2002 |